Newest FDA-approved opioid use disorder drug enters the market with flexible dosing
05 Oct 2023
The newest approved opioid use disorder drug is leaning on its flexible dosing schedule and injection site convenience to gain traction. Braeburn’s Brixadi can be administered as a weekly dose, but also as a monthly dose like its competitors. It also counts the drug’s lack of refrigeration needed and ability for injections at multiple sites on the body as additional differentiators.
“A weekly dose is important in this category in particular because clinicians like to see patients on a frequent basis especially early in the diagnosis or upon relapse,” Braeburn president and CEO Mike Derkacz said.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.